CytoDyn Inc.Long
Did CYDY $10 run set pace for even larger bullish trend channel?
After it's 10-day run to $10, CYDY did not hold expected support at $4.6. That turned out to be just A wave in ABC correction to $2.8 on unexpected FDA-imposed delay in HIV Combo BLA application. That was our most glaring miss in this series of CYDY projections. At least we see strong A=C proportionality suggesting the correction completed Monday the 13th: A=$10-$4.6=5.4 and C=$8-$2.86=5.14, though perfect proportionality would have taken price down to $2.6
CEO Nader said on Friday that data from Phase II mild/moderate COVID blind trial of 87 patients on leronlimab had been entered and locked but will take a few days to analyze. Assuming:
1) results are released late this week or early next, and
2) results are sufficiently positive to cause widespread speculation about FDA emergency approval in August,
Here's a bullish fractal path resuming strong share price growth at the pace set by the parabolic run to $10 -- which may have been just wave 1 of III towards $16-20.
It's not possible to create this projection from chart technicals alone -- we're combining the expected timing and bullish bias of upcoming news events with experience of how bullish fractal patterns evolve. Take this with a grain of salt -- if results are weaker than expected price may yet retest $2.6. On the other hand, none of us has seen how traders react to solid evidence of a highly effective treatment for an 8-month old worldwide pandemic. There could be crazy spikes into much higher double digits.
CEO Nader said on Friday that data from Phase II mild/moderate COVID blind trial of 87 patients on leronlimab had been entered and locked but will take a few days to analyze. Assuming:
1) results are released late this week or early next, and
2) results are sufficiently positive to cause widespread speculation about FDA emergency approval in August,
Here's a bullish fractal path resuming strong share price growth at the pace set by the parabolic run to $10 -- which may have been just wave 1 of III towards $16-20.
It's not possible to create this projection from chart technicals alone -- we're combining the expected timing and bullish bias of upcoming news events with experience of how bullish fractal patterns evolve. Take this with a grain of salt -- if results are weaker than expected price may yet retest $2.6. On the other hand, none of us has seen how traders react to solid evidence of a highly effective treatment for an 8-month old worldwide pandemic. There could be crazy spikes into much higher double digits.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.